+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates

Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates

Journal of ChemoTherapy 2(5): 295-299

The authors evaluated the in-vitro antibacterial activity of piperacillin alone and of piperacillin combined with tazobactam, a new beta-lactamase inhibitor, on 398 clinical isolates, both Gram-positive and Gram-negative. The piperacillin/tazobactam combination was evaluated in the fixed ratio 8:1. The vast majority of the microorganisms tested had reduced susceptibility to piperacillin (minimum inhibitory concentration (MIC) range 0.12- greater than 256 mg/l) due to beta-lactamase production. The following results were obtained: against Haemophilus influenzae, tazobactam was effective in reducing the MICs of piperacillin by 512 fold. The activity of piperacillin/tazobactam was lower against Pseudomonas sp., while some activity was demonstrated against some strains of Klebsiella. Good activity was seen not only against methicillin-susceptible (MS) staphylococci but also against some methicillin-resistant (MR) strains. In the latter, the combination of piperacillin/tazobactam was active only if the strains showed beta-lactamase production. These findings are interesting above all in regard to the synergistic effect demonstrated against MR beta-lactamase producing staphylococci and the Klebsiella-Enterobacter-Serratia (KES) group.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 039619223

Download citation: RISBibTeXText

PMID: 1965317

Related references

Activity of piperacillin and ticarcillin combined with tazobactam or clavulanic acid against beta lactamase producing piperacillin resistant isolates. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 32: 131, 1992

Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae. ChemoTherapy 44(6): 377-384, 1998

Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates. ChemoTherapy 36(5): 356-364, 1990

Comparative Activity of Piperacillin/Tazobactam against Clinical Isolates of Extended- Spectrum -Lactamase-Producing Enterobacteriaceae. Chemotherapy 44(6): 377-384, 1998

In vitro synergy studies based on tazobactam/piperacillin against clinical isolates of metallo-beta-lactamase-producing Pseudomonas aeruginosa. Journal of Antimicrobial ChemoTherapy 64(5): 1115-1116, 2009

Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clinical Microbiology and Infection 16(2): 132-136, 2010

Superior effect of tazobactam/piperacillin compared to piperacillin on beta-lactamase-producing Pseudomonas aeruginosa. ChemoTherapy 43(3): 171-178, 1997

Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients. Clinical Microbiology and Infection 9(11): 1128-1132, 2003

Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). Diagnostic Microbiology and Infectious Disease 12(6): 481-488, 1989

Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections. Journal of ChemoTherapy 9(2): 89-94, 1997

Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase. Diagnostic Microbiology and Infectious Disease 12(6): 511-515, 1989

Superior Effect of Tazobactam/ Piperacillin Compared to Piperacillin on -Lactamase-Producing Pseudomonas aeruginosa. Chemotherapy 43(3): 171-178, 1997

Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam. Brazilian Journal of Infectious Diseases 4(1): 22-28, 2000

Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca. ChemoTherapy 41(5): 345-352, 1995

Synergistic effect of polyethylenimine plus piperacillin/tazobactam on clinical Pseudomonas aeruginosa isolates resistant to piperacillin/tazobactam. Annals of Microbiology 56(4): 345-348, 2006